F Germino, MD
Internal Medicine · Orland Park, ILNPI 1962426239
Payments from drug & device makers
Across 155 payments — averaging $84.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$7K
- AstraZeneca$4K
- Boehringer Ingelheim$297
- Pfizer$285
- Novo Nordisk$276
- Amgen$157
- plus $820 from 17 others
What the payments were for
- Consulting fees$8,58566%
- Travel & lodging$1,89114%
- Food & beverage$2,56820%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $6,822 |
| AstraZeneca | 32 | $4,395 |
| Boehringer Ingelheim | 12 | $297 |
| Pfizer | 38 | $285 |
| Novo Nordisk | 14 | $276 |
| Amgen | 10 | $157 |
| Regeneron Healthcare Solutions, Inc. | 5 | $142 |
| GSK | 6 | $112 |
| Cranial Technologies, Inc | 6 | $83 |
| Merck | 4 | $71 |
| Exact Sciences | 4 | $67 |
| Corcept Therapeutics | 2 | $60 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $51 |
| Blueprint Medicines Corporation | 1 | $34 |
| Ionis Pharmaceuticals, Inc. | 1 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Abbott | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,053 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $187,760 |
| OzempicSemaglutide | 85 | $94,739 |
| Bydureon BciseExenatide Microspheres | 38 | $80,173 |
| TrulicityDulaglutide | 35 | $77,670 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $32,861 |
| RybelsusSemaglutide | 17 | $29,900 |
| FarxigaDapagliflozin Propanediol | 21 | $27,087 |
| JardianceEmpagliflozin | 18 | $22,640 |
| EntrestoSacubitril/Valsartan | 11 | $22,546 |
| JanuviaSitagliptin Phosphate | 14 | $22,187 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $17,832 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $14,235 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $12,833 |
| Atorvastatin Calcium | 814 | $9,313 |
| Losartan Potassium | 690 | $9,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $285 | $187,760133 claims |
| Novo NordiskOzempic, Rybelsus | $276 | $124,638102 claims |
| Lilly USA, LLCTrulicity | $15 | $77,67035 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $112 | $55,78260 claims |
| AstraZenecaFarxiga | $4,395 | $27,08721 claims |
| Boehringer IngelheimJardiance | $297 | $22,64018 claims |
| NovartisEntresto | $17 | $22,54611 claims |
| MerckJanuvia | $71 | $22,18714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Orland Park
- Yazen JoudehOrland Park$661K
- Nadia SiddiquiOrland Park$438K
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.